0
Cell and Gene Therapy Pipelines
0
Biopharma, Big Pharma, CMOs, and Research/Academic Institutes
0
Key Manufacturing Parameters
0
Key Pipeline Parameters
Tracker Highlights
left
right
comprehensive information

Competitive Assessment

This tracker provides an in-depth overview of the upcoming competition in the cell & gene therapy market of East-Asian countries.

Through this tracker IMAPAC aims to assist organizations to keep track of their competitors, identify any opportunities for collaboration or investments for development or manufacturing of cell & gene therapies and support key strategic decisions making for the business.

Explore More, Request A Demoright

Key Manufacturing Parameters

22+ parameters including facility centers, facility size, facility investment, production capacity, types of products manufactured in the facility, key features of the facility, operation scale, process technology, regulatory approvals & certifications, expansion plans and other vital information.

Explore More, Request A Demoright

Key Pipeline Parameters

More than 20 parameters such as company overview, current cell & gene therapy products in pipeline, product’s stage of development, product by therapy type, autologous or allogenic therapies, disease or indication, target for each product candidate, route of administration, and technology employed in product’s development.

Explore More, Request A Demoright

Key Companies Covered

JW Therapeutics, Hrain Biotechnology, GenomeFrontier Therapeutics, Takara Bio, Medipost, 3S Bio, MIimmune, Taiwan Biotherapeutics and other top cell & gene therapy companies in the region.

Explore More, Request A Demoright

Countries Coverage

Tracker includes China, Japan, South Korea, Hong Kong and Taiwan among others, from discovery to commercialization in a single platform.

Explore More, Request A Demoright
bag